Gugler R, Allgayer H
I. Medizinische Klinik, Stadt Karlsruhe, Federal Republic of Germany.
Clin Pharmacokinet. 1990 Mar;18(3):210-9. doi: 10.2165/00003088-199018030-00003.
Since a previous review by Hurwitz was published in 1977 a large number of reports on drug interactions with antacids have appeared, few of which are of clinical relevance. Tetracyclines form insoluble complex molecules by metal ion chelation with various antacids; tetracycline absorption may be decreased by more than 90% by this interaction. Of the new class of quinolone antibiotics, the absorption of ciprofloxacin and ofloxacin is reduced by 50 to 90% in the presence of aluminium- and magnesium hydroxide-containing antacids. In contrast to early work showing inhibition of the absorption of beta-adrenergic blocking drugs by antacids, subsequent studies did not confirm a reduction in the bioavailability of either atenolol or propranolol during antacid treatment; indeed, they showed an increase in the plasma concentrations of metoprolol when the drug was coadministered with an antacid. The bioavailability of captopril was significantly reduced in the presence of an antacid, and lower plasma concentrations of this angiotensin-converting enzyme inhibitor were accompanied by a reduction of its effect on the systolic blood pressure of the patients. The absorption of the cardiac glycosides digoxin and digitoxin is not inhibited by antacids to a significant degree, although earlier studies had shown a positive effect when the dissolution of the glycoside preparations was relatively poor. Antacids reduce the bioavailability of the H2-receptor antagonists cimetidine and ranitidine only when high antacid doses are used and when the drugs are administered simultaneously. The bioavailability of famotidine was not significantly altered by a potent antacid preparation, although a trend towards reduced absorption was observed. Iron absorption is significantly decreased in the presence of sodium bicarbonate and calcium carbonate, but is nearly complete when coadministered with aluminium-magnesium hydroxide. Nonsteroidal anti-inflammatory drugs such as naproxen, tenoxicam, ketoprofen, ibuprofen and piroxicam are not affected in their absorption by antacid treatment. Theophylline bioavailability is unchanged when the drug is given together with antacids, although its rate of absorption may be altered, leading to a reduction or an increase in the time of the occurrence of peak plasma drug concentrations.
自1977年赫维茨发表上一篇综述以来,出现了大量关于药物与抗酸剂相互作用的报告,但其中很少具有临床相关性。四环素通过与各种抗酸剂形成金属离子螯合物而形成不溶性复合分子;这种相互作用可使四环素的吸收减少90%以上。在新型喹诺酮类抗生素中,含铝和镁的抗酸剂会使环丙沙星和氧氟沙星的吸收减少50%至90%。与早期显示抗酸剂会抑制β-肾上腺素能阻滞剂吸收的研究不同,后续研究并未证实抗酸剂治疗期间阿替洛尔或普萘洛尔的生物利用度会降低;事实上,他们发现美托洛尔与抗酸剂同时给药时,其血浆浓度会升高。在抗酸剂存在的情况下,卡托普利的生物利用度显著降低,这种血管紧张素转换酶抑制剂的血浆浓度降低,同时其对患者收缩压的作用也减弱。尽管早期研究表明在糖苷制剂溶解相对较差时抗酸剂有积极作用,但抗酸剂对强心苷地高辛和洋地黄毒苷的吸收没有显著抑制作用。只有在使用高剂量抗酸剂且同时给药时,抗酸剂才会降低H2受体拮抗剂西咪替丁和雷尼替丁的生物利用度。一种强效抗酸剂制剂并未显著改变法莫替丁的生物利用度,尽管观察到有吸收减少的趋势。在碳酸氢钠和碳酸钙存在的情况下,铁的吸收会显著降低,但与铝镁氢氧化合物共同给药时,铁的吸收几乎是完全的。抗酸剂治疗对萘普生、替诺昔康、酮洛芬、布洛芬和吡罗昔康等非甾体抗炎药的吸收没有影响。茶碱与抗酸剂一起给药时,其生物利用度不变,尽管其吸收速率可能会改变,导致血浆药物浓度达峰时间缩短或延长。